the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.
Also called NCT06650007
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 218 participants
- Registry
-
NCT06650007
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06650007. Randomized; double masking; primary purpose treatment. Start 2024-11-08 (actual); primary completion 2026-01-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- HRS9531 Injection
- Intervention (Drug)
- HRS9531 Placebo Injection
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06650007- Content hash
ed979640be845806a34c7e4f28d89d6a7c2a4b87958698e531cfa390f8821394